The role of prostate-specific antigen in the prediction of hormone-sensitive prostate cancer

Abstract

429 patients with histologically confirmed prostate cancer undergoing various treatment from 1995 till 2014 were studied retrospectively. Overall survival with the baseline PSA less than 30 ng/ml averaged 50.5 months; with higher rates of PSA, the lifespan was reduced to 28 months regardless of treatment. The cause of death of 150 (35%) patients with PSA below 30ng/ml was not an oncological disease. Even with the initial PSA more than 30 ng/ml, 39 patients (9.1%) died from comorbidities. PSA above 30 ng/ml is a poor prognostic factor requiring a more aggressive approach to the treatment of these patients. Gleason score above 7 points is associated with a worse life expectancy forecast as well as a considerable decrease in the quality of life. PSA level determination continues to play a key role in the early detection of prostate cancer.